Pharmaceutical and diagnostics company Roche has incorporated AI algorithms into its digital pathology software, collaborating with South Korean firm Deep Bio to enhance the navify platform with the DeepDx Prostate AI solution for prostate cancer analysis. DeepDx Prostate offers detailed gland-level grading, tissue measurements, and support for diagnosis. Qritive, a Singapore-based company, has also integrated its digital pathology AI solutions into Roche’s navify, focusing on cancers like colon, prostate, breast, and gastric cancers. Additionally, Indian mental health startup Wundrsight has received $400,000 in seed funding to develop VR-based digital therapeutics for mental health issues like substance use disorders, OCD, anxiety, and autism, with plans to expand partnerships in India and increase access to its solutions in hospitals.
Source link
Roche boosts digital pathology with AI and more briefs
